We found that participants with sarcopenia at baseline had a 2-fold higher risk of irAEs on anti-PD-1/L1 therapy than participants without sarcopenia, and that the risk was 5-fold higher in patients with sarcopenia combined with overweight/obesity. This evidence concerns the gene PDCD1 and sarcopenia.